Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease-Reference-Cited by-同舟云学术

Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease

Published:2018-01-07 Issue:2 Volume:21 Page:477-486
ISSN:1756-1841
Container-title:International Journal of Rheumatic Diseases
language:en
Short-container-title:Int J Rheum Dis

Author:

Xiao Hua¹²³,Zhang Guang-feng¹²,Liao Xiang-ping³,Li Xiao-jie⁴,Zhang Jian⁵,Lin Haobo¹²,Chen Zhe³,Zhang Xiao¹²^ORCID

Affiliation:

1. Southern Medical University; Guangzhou China

2. Department of Rheumatology; Guangdong General Hospital; Guangdong Academy of Medical Sciences; Guangzhou China

3. Department of Rheumatology; The First Peoples’ Hospital of Chenzhou; Hunan China

4. Department of Pathology; The First Peoples’ Hospital of Chenzhou; Hunan China

5. Statistics of Translational Medicine Institute; National and Local Joint Engineering Laboratory for High-Through Molecular Diagnosis Technology; The First Peoples’ Hospital of Chenzhou; Hunan China

Funder

Foundation of Outstand Young of the First Peoples' Hospital of Chenzhou

Publisher

Wiley

Subject

Rheumatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1756-185X.13247/fullpdf

Reference35 articles.

1. Changes in causes of death in systemic sclerosis, 1972-2002;Steen;Ann Rheum Dis,2007

2. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis;Clements;Ann Rheum Dis,2007

3. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis;King;N Engl J Med,2014